1-5 of 5
Andrew Krivoshik
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

Helena A. Yu, Alexander Spira, Leora Horn, Jared Weiss, Howard West, Giuseppe Giaccone, Tracey Evans, Ronan J. Kelly, Bhardwaj Desai, Andrew Krivoshik, Diarmuid Moran, Srinivasu Poondru, Fei Jie, Kouji Aoyama, Anne Keating, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (24): 7467–7473.
https://doi.org/10.1158/1078-0432.CCR-17-1447
Published: 14 December 2017
View article titled, A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations
Open the PDF for A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Enzalutamide Prior to Prostatectomy

Bruce Montgomery, Maria S. Tretiakova, Anthony M. Joshua, Martin E. Gleave, Neil Fleshner, Glenn J. Bubley, Elahe A. Mostaghel, Kim N. Chi, Daniel W. Lin, Martin Sanda, William Novotny, Kenneth Wu, Philip W. Kantoff, Brett T. Marck, Stephen Plymate, Steven P. Balk, Peter S. Nelson, Alvin M. Matsumoto, Rosina T. Lis, Adam Kibel, Gabriel P. Haas, Andrew Krivoshik, Alison Hannah, Mary-Ellen Taplin
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (9): 2169–2176.
https://doi.org/10.1158/1078-0432.CCR-16-1357
Published: 30 April 2017
View article titled, Neoadjuvant Enzalutamide Prior to Prostatectomy
Open the PDF for Neoadjuvant Enzalutamide Prior to Prostatectomy in another window
Includes: Supplementary data
Journal Articles

BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

Al B. Benson, III, Igor Kiss, John Bridgewater, Ferry A.L.M. Eskens, Carolyn Sasse, Sandra Vossen, Jihong Chen, Chip Van Sant, Howard A. Ball, Anne Keating, Andrew Krivoshik
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (20): 5058–5067.
https://doi.org/10.1158/1078-0432.CCR-15-3117
Published: 13 October 2016
View article titled, BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer
Open the PDF for BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors

Elizabeth Fox, John M. Maris, Brigitte C. Widemann, Wendy Goodspeed, Anne Goodwin, Marie Kromplewski, Molly E. Fouts, Diane Medina, Susan L. Cohn, Andrew Krivoshik, Anne E. Hagey, Peter C. Adamson, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (4): 1111–1115.
https://doi.org/10.1158/1078-0432.CCR-07-4097
Published: 15 February 2008
View article titled, A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors
Open the PDF for A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors in another window
Journal Articles

A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors

Elizabeth Fox, John M. Maris, Brigitte C. Widemann, Kysa Meek, Anne Goodwin, Wendy Goodspeed, Marie Kromplewski, Molly E. Fouts, Diane Medina, Steve Y. Cho, Susan L. Cohn, Andrew Krivoshik, Anne E. Hagey, Peter C. Adamson, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (16): 4882–4887.
https://doi.org/10.1158/1078-0432.CCR-06-0534
Published: 16 August 2006
View article titled, A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors
Open the PDF for A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors in another window